Additionally, I am sure they can afford to buy those back at $1 or higher if they so choose. Once Nuvilex has a demand for Cell-in-a-Box(R) which is certain to happen with FDA approval if Dr Von Hoff works his magic again, many will be interested in owning a piece of the pie. And Fisher Asset Management, like us, continues to wait and hold.